Back to Search Start Over

Parkinsons disease variant detection and disclosure: PD GENEration, a North American study.

Authors :
Cook, Lola
Cook, Lola
Verbrugge, Jennifer
Schwantes-An, Tae-Hwi
Schulze, Jeanine
Foroud, Tatiana
Hall, Anne
Marder, Karen
Mata, Ignacio
Mencacci, Niccolò
Nance, Martha
Schwarzschild, Michael
Simuni, Tanya
Bressman, Susan
Wills, Anne-Marie
Fernandez, Hubert
Litvan, Irene
Lyons, Kelly
Shill, Holly
Singer, Carlos
Tropea, Thomas
Vanegas Arroyave, Nora
Carbonell, Janfreisy
Cruz Vicioso, Rossy
Katus, Linn
Quinn, Joseph
Hodges, Priscila
Meng, Yan
Strom, Samuel
Blauwendraat, Cornelis
Lohmann, Katja
Casaceli, Cynthia
Rao, Shilpa
Ghosh Galvelis, Kamalini
Naito, Anna
Beck, James
Alcalay, Roy
Cook, Lola
Cook, Lola
Verbrugge, Jennifer
Schwantes-An, Tae-Hwi
Schulze, Jeanine
Foroud, Tatiana
Hall, Anne
Marder, Karen
Mata, Ignacio
Mencacci, Niccolò
Nance, Martha
Schwarzschild, Michael
Simuni, Tanya
Bressman, Susan
Wills, Anne-Marie
Fernandez, Hubert
Litvan, Irene
Lyons, Kelly
Shill, Holly
Singer, Carlos
Tropea, Thomas
Vanegas Arroyave, Nora
Carbonell, Janfreisy
Cruz Vicioso, Rossy
Katus, Linn
Quinn, Joseph
Hodges, Priscila
Meng, Yan
Strom, Samuel
Blauwendraat, Cornelis
Lohmann, Katja
Casaceli, Cynthia
Rao, Shilpa
Ghosh Galvelis, Kamalini
Naito, Anna
Beck, James
Alcalay, Roy
Source :
Brain; vol 147, iss 8
Publication Year :
2024

Abstract

Variants in seven genes (LRRK2, GBA1, PRKN, SNCA, PINK1, PARK7 and VPS35) have been formally adjudicated as causal contributors to Parkinsons disease; however, individuals with Parkinsons disease are often unaware of their genetic status since clinical testing is infrequently offered. As a result, genetic information is not incorporated into clinical care, and variant-targeted precision medicine trials struggle to enrol people with Parkinsons disease. Understanding the yield of genetic testing using an established gene panel in a large, geographically diverse North American population would help patients, clinicians, clinical researchers, laboratories and insurers better understand the importance of genetics in approaching Parkinsons disease. PD GENEration is an ongoing multi-centre, observational study (NCT04057794, NCT04994015) offering genetic testing with results disclosure and genetic counselling to those in the US (including Puerto Rico), Canada and the Dominican Republic, through local clinical sites or remotely through self-enrolment. DNA samples are analysed by next-generation sequencing including deletion/duplication analysis (Fulgent Genetics) with targeted testing of seven major Parkinsons disease-related genes. Variants classified as pathogenic/likely pathogenic/risk variants are disclosed to all tested participants by either neurologists or genetic counsellors. Demographic and clinical features are collected at baseline visits. Between September 2019 and June 2023, the study enrolled 10 510 participants across >85 centres, with 8301 having received results. Participants were: 59% male; 86% White, 2% Asian, 4% Black/African American, 9% Hispanic/Latino; mean age 67.4 ± 10.8 years. Reportable genetic variants were observed in 13% of all participants, including 18% of participants with one or more high risk factors for a genetic aetiology: early onset (<50 years), high-risk ancestry (Ashkenazi Jewish/Basque/North African Berber), an affected first-d

Details

Database :
OAIster
Journal :
Brain; vol 147, iss 8
Notes :
application/pdf, Brain vol 147, iss 8
Publication Type :
Electronic Resource
Accession number :
edsoai.on1452693432
Document Type :
Electronic Resource